The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy : results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial
- Author
- Richard J Sylvester, Adrian PM van der Meijden, Willem Oosterlinck (UGent) , Wolfgang Hoeltl and Aldo V Bono
- Organization
- Keywords
- adverse effects, INTRAVESICAL BCG, efficacy, mycobacterium bovis, transitional cell carcinoma, RISK, bladder neoplasms, TUMORS, TOXICITY, URINARY INTERLEUKIN-8, METAANALYSIS, IMMUNOTHERAPY, THERAPY, TRANSITIONAL-CELL CARCINOMA
Downloads
-
(...).pdf
- full text
- |
- UGent only
- |
- |
- 155.89 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-285259
- MLA
- Sylvester, Richard J., et al. “The Side Effects of Bacillus Calmette-Guerin in the Treatment of Ta T1 Bladder Cancer Do Not Predict Its Efficacy : Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial.” EUROPEAN UROLOGY, vol. 44, no. 4, 2003, pp. 423–28, doi:10.1016/S0302-2838(03)00371-3.
- APA
- Sylvester, R. J., van der Meijden, A. P., Oosterlinck, W., Hoeltl, W., & Bono, A. V. (2003). The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy : results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial. EUROPEAN UROLOGY, 44(4), 423–428. https://doi.org/10.1016/S0302-2838(03)00371-3
- Chicago author-date
- Sylvester, Richard J, Adrian PM van der Meijden, Willem Oosterlinck, Wolfgang Hoeltl, and Aldo V Bono. 2003. “The Side Effects of Bacillus Calmette-Guerin in the Treatment of Ta T1 Bladder Cancer Do Not Predict Its Efficacy : Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial.” EUROPEAN UROLOGY 44 (4): 423–28. https://doi.org/10.1016/S0302-2838(03)00371-3.
- Chicago author-date (all authors)
- Sylvester, Richard J, Adrian PM van der Meijden, Willem Oosterlinck, Wolfgang Hoeltl, and Aldo V Bono. 2003. “The Side Effects of Bacillus Calmette-Guerin in the Treatment of Ta T1 Bladder Cancer Do Not Predict Its Efficacy : Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial.” EUROPEAN UROLOGY 44 (4): 423–428. doi:10.1016/S0302-2838(03)00371-3.
- Vancouver
- 1.Sylvester RJ, van der Meijden AP, Oosterlinck W, Hoeltl W, Bono AV. The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy : results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial. EUROPEAN UROLOGY. 2003;44(4):423–8.
- IEEE
- [1]R. J. Sylvester, A. P. van der Meijden, W. Oosterlinck, W. Hoeltl, and A. V. Bono, “The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy : results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial,” EUROPEAN UROLOGY, vol. 44, no. 4, pp. 423–428, 2003.
@article{285259, author = {{Sylvester, Richard J and van der Meijden, Adrian PM and Oosterlinck, Willem and Hoeltl, Wolfgang and Bono, Aldo V}}, issn = {{0302-2838}}, journal = {{EUROPEAN UROLOGY}}, keywords = {{adverse effects,INTRAVESICAL BCG,efficacy,mycobacterium bovis,transitional cell carcinoma,RISK,bladder neoplasms,TUMORS,TOXICITY,URINARY INTERLEUKIN-8,METAANALYSIS,IMMUNOTHERAPY,THERAPY,TRANSITIONAL-CELL CARCINOMA}}, language = {{eng}}, number = {{4}}, pages = {{423--428}}, title = {{The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy : results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial}}, url = {{http://doi.org/10.1016/S0302-2838(03)00371-3}}, volume = {{44}}, year = {{2003}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: